Cardiology patients with OSA


Obstructive sleep apnea is found in approximately 40-60% of people with cardiovascular disease. Cardiologists are able to provide these patients with a convenient and cost-effective manner to test for sleep conditions.

How many patients do you see per day?
What is your medical specialty?
Average HST reimbursement*
Days per Month 20 20
95806 Global Medicare HST Revenue

Partnering with DreamClear™

A home sleep testing device, like DreamClear™, makes the entire process simple for providers and patients. The REMware team handles the details, from end-to-end if desired, and patients benefit from the most advanced home testing program available.

Benefits of DreamClear™ for Cardiologists

The link between obstructive sleep apnea and cardiovascular disease is increasing in prevalence as more research is conducted. It is important for cardiologists to diagnose and test for sleep disorders which can have a negative effect on the cardiovascular system if left untreated.

Since there is often a correlation between obstructive sleep apnea and hypertension, DreamClear™ helps patients test for sleep apnea conveniently without needing to visit a lab. Patients receive results through an app-based platform, which significantly speeds up the process.

Manage Sleep-Related Issues with DreamClear™

Cardiologists should recommend a sleep study when patients are being treated for cardiovascular disease, hypertension, and stroke. DreamClear™ enables the patient to perform the test from home and has the ability to provide streamlined interpretation services via the cloud based platform. The data transfer process occurs within 30 minutes of waking up through the mobile app and interpretation can often be completed the same day.

To learn more about using DreamClear™ to help treat patients with cardiovascular disease, download our brochure today.

Ready to get started?

(813) 364-2712

Call for participation and early trial information.
Learn how easy DreamClear makes it for you to increase practice revenue.